Alignment Healthcare, Inc. SEC Filings

Alignment Healthcare insider Christopher J. Joyce, the companys Chief Legal and Administrative Officer and a director, reported two non-discretionary sales of common stock on 09/10/2025 to satisfy tax withholding for vested restricted stock units. Mr. Joyce sold 22,128 shares at a weighted-average price of $16.2293 (per-share trades ranged $15.74$16.735) and 8,811 shares at a weighted-average price of $16.8555 (per-share trades ranged $16.74$17.24). After these transactions he beneficially owns 352,403 and 343,592 shares as reported on each line, respectively. The filer certified the sales were to cover tax withholding and not discretionary trades.

Robert L. Scavo, Chief Information Officer and director of Alignment Healthcare, Inc. (ALHC), sold shares on 09/10/2025 to satisfy tax withholding from RSU vesting. The filing reports two non-discretionary sales: 21,123 shares at a weighted-average price of $16.2293 (individual trade prices ranged $15.74 to $16.735) and 8,412 shares at a weighted-average price of $16.8555 (individual trade prices ranged $16.74 to $17.24). After these transactions he beneficially owned 580,967 shares following the first set and 572,555 shares following the second set, held directly. The sales were executed pursuant to tax-withholding obligations and were not discretionary trades.

Alignment Healthcare insider sale under 10b5-1 plan; sales were tax-withholding for vested RSUs. On 09/10/2025 Dawn C. Maroney reported three non-discretionary sales of Alignment Healthcare (ALHC) common stock. The reported transactions were: sale of 77,555 shares at a weighted-average price of $16.2293 (per-share sales ranged $15.74–$16.735), sale of 30,884 shares at a weighted-average price of $16.8555 (range $16.74–$17.24), and sales totaling 107,223 shares under a Rule 10b5-1 plan adopted 05/22/2025 at a weighted-average price of $16.4163 (range $16.03–$16.73). Following these transactions the reporting person beneficially owned 1,797,237 shares.

Joseph S. Konowiecki, a director of Alignment Healthcare, Inc. (ALHC), reported a sale of 25,000 shares of the company's common stock on 09/09/2025 at a price of $17 per share. After the reported transaction he beneficially owned 1,127,049 shares, held directly. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on 03/05/2025, and the Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure is limited to this single non-derivative sale and ownership snapshot; no options, acquisitions, or other transactions are reported.

John E. Kao, Alignment Healthcare (ALHC) Chief Executive Officer and Director, reported multiple stock sales on 09/10/2025. The Form 4 shows three non-derivative disposition entries: 253,908 shares sold at a weighted-average price of $16.2293 (per-share range $15.74–$16.735), 101,110 shares sold at a weighted-average price of $16.8555 (per-share range $16.74–$17.24), and 180,000 shares sold under a Rule 10b5-1 plan at a weighted-average price of $16.4164 (per-share range $16.03–$16.73). The first two sales were to cover tax withholding on vested restricted stock units and are described as non-discretionary; the 180,000-share sale was executed under a pre-established 10b5-1 plan adopted 03/12/2025. Following the reported transactions, the filing indicates beneficial ownership figures of 4,634,678 shares, 4,533,568 shares, and an indirect holding of 1,193,100 shares through the JEK Trust (dated February 8, 2021) for which Mr. Kao is trustee.

Alignment Healthcare, Inc. (ALHC) Form 144 notifies a proposed sale of 430,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $7,086,400 and approximately 198,031,000 shares outstanding. The shares were acquired as restricted stock units on 03/25/2025. The filing lists the approximate sale date as 09/10/2025. The filing also discloses prior sales by JEK TRUST U/A DTD 02/08/2021 totaling 895,018 shares across June–September 2025 under 10b5-1 plans and direct sale, with listed gross proceeds for each sale. The notice includes required representations about material nonpublic information and 10b5-1 plan adoption language.

Alignment Healthcare, Inc. (ALHC) filing a Form 144 reports a proposed sale of 107,223 common shares through Morgan Stanley Smith Barney LLC on 09/10/2025 for an aggregate market value of $1,767,035.04, with the securities to be sold on NASDAQ. The shares were acquired as restricted stock units on 09/07/2025 and payment is recorded as N/A. The filing also discloses prior sales by Dawn Maroney: 108,439 shares on 09/08/2025 (gross proceeds $1,779,483.99) and three earlier 10b5-1 plan sales of 30,000 shares each on 08/13/2025, 07/14/2025, and 06/16/2025 with stated gross proceeds. The filer attests there is no undisclosed material adverse information.

Alignment Healthcare, Inc. (ALHC) Form 144 notice reports a proposed sale of 25,000 common shares through broker Justin Tabit, with an aggregate market value of $423,750.00. The filing states the issuer has 198,031,417 shares outstanding and lists an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 10/06/2014 as a stock bonus from Joseph Konowiecki, and the original acquisition record shows 323,139 shares acquired with payment characterized as compensation. The filing also discloses a sale during the past three months: 25,000 shares sold on 07/31/2025 for gross proceeds of $398,750.00 by Joseph Konowi.